CHMA Chiasma Inc.

1.85
+0.00  (0%)
Previous Close 1.85
Open 1.90
Price To book 0.66
Market Cap 45101550
Shares 24,379,216
Volume 18,382
Short Ratio 6.54
Av. Daily Volume 60,522

SEC filingsSee all SEC filings

  1. 8-K - Current report 171208209
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171191213
  3. 8-K - Current report 171190980
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021682
  5. 8-K - Current report 171021563

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to commence enrollment 2H 2017 with data due 2019.
Mycapssa - OPTIMAL
Acromegaly
CRL April 15 2016
Mycapssa
Acromegaly
Phase 3 data due 2020.
Mycapssa - MPOWERED
Maintenance treatment of adult acromegaly

SEC Filings

  1. 8-K - Current report 171208209
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171191213
  3. 8-K - Current report 171190980
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171021682
  5. 8-K - Current report 171021563
  6. 8-K - Current report 17917508
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17816157
  8. 8-K - Current report 17816140
  9. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17784948
  10. DEF 14A - Other definitive proxy statements 17781701